Trial Profile
A randomized controlled study comparing S-1 with UFT as postoperative adjuvant Chemotherapy in Rectal Cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Oct 2017
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Tegafur/uracil
- Indications Rectal cancer
- Focus Therapeutic Use
- Acronyms ACTS-RC
- 12 Sep 2017 Results of exploratory analysis assessing effect of lateral lymph node dissection for lower rectal cancer in patients receiving either UFT or S-1 therapy, were presented at the 42nd European Society for Medical Oncology Congress.
- 22 Jun 2015 Planned End Date changed from 1 Mar 2014 to 1 Apr 2014 as reported by the University Hospital Medical Information Network - Japan record.
- 29 May 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.